FDA says Teva antidepressant is ineffective

FDA tells Teva to withdraw its generic antidepressant, saying it does not work properly By Matthew Perrone, AP Health Writer WASHINGTON (AP) — Teva Pharmaceuticals has stopped ...

J&J and Astellas Collaborate

By Zacks Equity Research Johnson & Johnson’s (JNJ) Janssen Biotech, Inc. recently entered into a licensing agreement with Astellas Pharma Inc. for the latter’s Janus kinase ...

Celgene’s Pipeline Offers Catalysts Into 2013

I last updated my thoughts on Celgene (CELG) in June, writing how the sell-off tied to the FDA approval of competitor Onyx Pharmaceuticals (ONXX) Krypolis was overdone. Celgene shares ...

Merck Shrugs off Patent Worries, Eyes China

By Peter Pham Peter is a member of The Motley Fool Blog Network — entries represent the personal opinions of our bloggers and are not formally edited. The German employees of Merck (NYSE: MRK) are ...

GlaxoSmithKline Reports Completion Of Dolutegravir Registration Package

(RTTNews.com) – GlaxoSmithKline Plc (GSK, GSK.L) said Shionogi-ViiV Healthcare LLC, a joint venture between ViiV Healthcare Ltd. and Shionogi & Co., Ltd., completed clinical ...

Analysis: Maturing Belgian biotechs outshine European peers

By Ben Deighton (Reuters) – From its base in a business park outside the city of Ghent, Belgium’s biotech industry is attracting a global following, benefiting from years ...

Pfizer’s Prevenar 13 vaccine meets trial goal

(Reuters) – Pfizer Inc said a late-stage study of its Prevenar 13 vaccine met the main trial goal, and the data will help to expand a European regulatory application for the vaccine. The ...

Sanofi Defends Lyxumia Under Scrutiny at Diabetes Meeting

By Albertina Torsoli Sanofi (SAN) defended its experimental drug Lyxumia after some scientists questioned the medicine’s novelty at a diabetes conference. Lyxumia isn’t “at all” ...

3 Things to Watch With Celldex Therapeutics

By Keith Speights While headlines blared the spectacular successes and failures of some biotech companies over the last couple of months, Massachusetts-based Celldex Therapeutics(Nasdaq: CLDX  ) plugged ...

Former FDA chief says J&J broke law promoting Risperdal, Philly Inquirer says

Theflyonthewall.com David Kessler, the former commissioner of the Food and Drug Administration, said that Johnson & Johnson (JNJ) broke the law in marketing its antipsychotic drug ...

3 Interesting Moves In Biotech Stocks From Wednesday

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) Normally I post my daily dose of three biotech/pharma ...

Endo Health sees weak 2013 profit on generic threat to key drug

(Reuters) – Endo Health Solutions forecast 2013 earnings below market expectations as its pain-relieving patch Lidoderm, the company’s biggest revenue driver, will face ...
Page 5 of 105« First...34567...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS